A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents.

Abstract

Systemic agents such as methotrexate and cyclosporine are commonly used in the treatment of psoriasis. Long-term continuous use is not recommended due to potential organ toxicity, myelosuppression, and carcinogenicity. Abrupt cessation of systemic agents without tapering can lead to flare-up and rebound of psoriasis. The addition of a biologic agent during transitional therapy from a systemic agent is a good strategic maneuver to prevent a potential rebound complication. Even with a gradual cessation of systemic agents, the psoriasis will eventually relapse if biologic agents are not added to the treatment regimen. No additional toxicities or adverse events are evident during combination therapy with a systemic agent and a biologic agent.

• Authors: Arisa Ortiz, Paul S Yamauchi
• Journal: Skinmed (Skinmed) 2006 Nov-Dec Vol. 5 Issue 6 Pg. 285-8 ISSN: 1540-9740 [Print] United States
• PMID: 17085995 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Dermatologic Agents
• Immunoglobulin G
• Immunologic Factors
• Receptors, Tumor Necrosis Factor
• Recombinant Fusion Proteins
• Cyclosporine
• Alefacept
• Acitretin
• Etanercept
• efalizumab
• Methotrexate

Topics

• Acitretin (administration & dosage)
• Administration, Oral
• Alefacept
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Cyclosporine (administration & dosage)
• Dermatologic Agents (administration & dosage)
• Drug Administration Schedule
• Etanercept
• Humans
• Immunoglobulin G (administration & dosage)
• Immunologic Factors (administration & dosage)
• Methotrexate (administration & dosage)
• Psoriasis (drug therapy, pathology)
• Receptors, Tumor Necrosis Factor (administration & dosage)
• Recombinant Fusion Proteins (administration & dosage)
• Severity of Illness Index